Attorney Thomas Renz found information about Pfizer's initial biologics license application regarding the use of Wuhan coronavirus (COVID-19) vaccines for individuals 16 years and older. According to the Ohio-based lawyer, it does not look good for the authorities.
Renz said the Food and Drug Administration published a package insert that listed two new National Drug Codes and images of labels with the new trade name.
"What that means in English is that Pfizer didn't make any common research and development (R&D) and it's not going to make any common R&D. This whole common license thing was a load of crap to try and convince people to get these jabs," Renz told Pastor David Scarlett during the June 10 episode of "HIS Glory" on Brighteon.TV.
While everybody thinks the process is done through the Department of Health and Human Services (HHS), it appears that the testing and approval process has been done through the military so that Pfizer can dodge the licensing and procurement requirements. "It is so corrupt. It is mind-blowing," Renz remarked. (Related: COVID vaccine injury reports jump by 27,000 in one week, FDA pulls 'bait and switch' with Pfizer vaccine approval.)
The information was quietly hidden away on the Centers for Disease Control and Prevention website. Renz himself admitted that he didn't notice the information until it was laid out in front of him. "These people are inept. They've declared war on America, and what they're doing is horrific beyond words. This is neither legal, nor is it acceptable," said Renz, the host of "Lawfare with Tom Renz."
Two whistleblowers have come forward with information about Pfizer's military backing, Scarlett noted. Renz's information confirmed that it was the military – and not the HHS – running the vaccination program.
Army begins human trials of pan-coronavirus vaccines
Because the COVID-19 vaccines were becoming less effective against infections with the B16172 delta and B11529 omicron variants, researchers turned toward the development of pan-coronavirus vaccines that could work effectively against multiple variants. Researchers from the Walter Reed National Military Medical Center (WRNMC) in Maryland have been doing so over the past two years and have announced they were testing the vaccines in humans in a Phase 1 study.
COVID-19 vaccines manufactured and distributed by Pfizer and Moderna use mRNA protein from the SARS-CoV-2 virus to instruct the body's cells to create immune responses. Specifically, the mRNA instructs the cells to recognize specific proteins on the virus surface. However, this spike protein has mutated in recent variants, causing the vaccines to be slightly less effective.
To mitigate the issues caused by the mutating virus, WRNMC researchers found a way to create a vaccine that can recognize multiple spike proteins at once, which can produce an array of varying coronavirus antigens.
The researchers then moved to test the vaccine in humans in a Phase I clinical study, stating that they will test the effect of vaccine-induced antibodies against known SARS-CoV-2 variants, including omicron. They added that they will also investigate the vaccine's safety in those who have been previously vaccinated, and in those that have been infected by the virus. (Related: Pfizer modifies COVID vaccine formulation for children, secretly adding heart attack drug that presents new health risks.)
By working with military research groups, Pfizer is skirting rules and regulations and is experimenting on those who are serving and who put their lives on the line. "The troops have become guinea pigs and cannon fodder, which is not OK," Scarlett said.
Visit Vaccines.news for more news related to COVID-19 vaccines.
Watch the full June 10 episode of "HIS Glory" below. "HIS Glory" airs every Friday at 5-6 p.m. and every Sunday at 2-3 p.m. on Brighteon.TV.
More related stories:
Former Pfizer employee flags FDA study, warns that Pfizer vaccine increases COVID by over 300%.
Leaked emails reveal COLLUSION between three major drug regulators to approve Pfizer vaccine.
Sources include:
Please contact us for more information.